# Safety and Tolerability of AGN-199201 in Patients With Erythema Associated With Rosacea

> **NCT01579084** · PHASE1 · COMPLETED · sponsor: **Allergan** · enrollment: 64 (actual)

## Conditions studied

- Rosacea
- Erythema

## Interventions

- **DRUG:** AGN-199201 Formulation A
- **DRUG:** AGN-199201 Formulation B
- **DRUG:** AGN-199201 Formulation C
- **DRUG:** AGN-199201 Vehicle

## Key facts

- **NCT ID:** NCT01579084
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04
- **Primary completion:** 2012-06
- **Final completion:** 2012-06
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2019-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01579084

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01579084, "Safety and Tolerability of AGN-199201 in Patients With Erythema Associated With Rosacea". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01579084. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*